Program
volrustomig
Also written as “Volrustomig”, “MEDI5752” and “AZD9592 + Volrustomig”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Carcinoma, Renal Cell, led by 2 companies.
Drug pageVolrustomig: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 1716 open or running | phase 3since Aug 2, 2023 | Mar 28, 2018 | Jan 29, 2027phase 1 · NCT07000149 |
| Presage Biosciencesits history only | 21 open or running | early phase 1since Sep 1, 2020 | Sep 1, 2020 | Dec 2031early phase 1 · NCT04541108 |
- Named in AstraZeneca’s own pipeline as
volrustomig
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Parexel, Daiichi Sankyo and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Mar 28, 2018.
- Jul 22, 2020Phase 1 study in Carcinoma, Renal CellNCT04522323 · 67 enrolled · United States, Australia, France and more
- Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550 · 630 planned · United States, Belgium, Canada and more
- Jul 21, 2022Named volrustomigINNProposed as its International Nonproprietary Name in WHO's List 127 · before, MEDI5752
- Nov 9, 2022Phase 1 study in Advanced Solid TumorsNCT05685472 · 6 enrolled · Japan
- Dec 7, 2022Phase 2 study in Stomach NeoplasmsNCT05702229 · 163 planned · United States, China, Japan and more
- Mar 2, 2023Phase 2 study in Carcinoma, HepatocellularNCT05775159 · 294 enrolled · United States, China, Hong Kong and more
- Aug 2, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05984277 · 895 enrolled · United States, Argentina, Australia and more
- Sep 4, 2023Phase 3 study in Locally Advanced Cervical CancerNCT06079671 · 800 planned · United States, Brazil, Canada and more
- Oct 4, 2023Phase 3 study in MesotheliomaNCT06097728 · 863 enrolled · United States, Australia, Belgium and more
- Nov 3, 2023Phase 3 study in Locally Advanced Head and Neck Squamous Cell CarcinomaNCT06129864 · 1,145 planned · United States, Austria, Belgium and more
- Jun 4, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06448754 · 194 enrolled · United States, China, France and more
- Jul 31, 2024Phase 2 study in Uterine Cervical NeoplasmsNCT06535607 · 257 planned · United States, Australia, Brazil and more
- Jan 20, 2025Phase 2 study in Colorectal NeoplasmsNCT06792695 · 82 enrolled · United States, Australia, Canada and more
- Mar 11, 2025Phase 2 study in Locally Advanced Cervical CancerNCT06943833 · 37 enrolled · Russia
- May 23, 2025Phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12NCT07000149 · 9 enrolled · Australia, South Korea
Ahead
- Jan 29, 2027Primary completion: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12NCT07000149
- May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT04379596
- Jun 30, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT06792695
- Jul 30, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06448754
TargetBeta
“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CT…”NCIt, read by Claude
“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 17 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07000149Diabetes Mellitus, Insulin-Dependent, 12 · Australia, South Korea | 1 | Active, not recruiting | Jan 29, 2027 | 9 |
| NCT06943833Locally Advanced Cervical Cancer · Russia | 2 | Active, not recruiting | Mar 13, 2028 | 37 |
| NCT06792695Colorectal Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Jun 30, 2027 | 82 |
| NCT06535607Uterine Cervical Neoplasms · United States, Australia, Brazil and more | 2 | Recruiting | Nov 30, 2028 | 257 |
| NCT06448754Carcinoma, Non-Small-Cell Lung · United States, China, France and more | 2 | Active, not recruiting | Jul 30, 2027 | 194 |
| NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma · United States, Austria, Belgium and more | 3 | Recruiting | Apr 17, 2030 | 1,145 |
| NCT06097728Mesothelioma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Nov 16, 2028 | 863 |
| NCT06079671Locally Advanced Cervical Cancer · United States, Brazil, Canada and more | 3 | Recruiting | Nov 26, 2027 | 800 |
| NCT05984277Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 17, 2026 | 895 |
| NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more | 2 | Active, not recruiting | Oct 27, 2026 | 294 |
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | Nov 30, 2027 | 163 |
| NCT05685472Advanced Solid Tumors · Japan | 1 | Completed | Aug 8, 2023 | 6 |
| NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Recruiting | May 28, 2030 | 630 |
| NCT04522323Carcinoma, Renal Cell · United States, Australia, France and more | 1 | Active, not recruiting | Sep 26, 2025 | 67 |
| NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more | 2 | Active, not recruiting | May 4, 2027 | 452 |
| NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 1 | Active, not recruiting | May 23, 2023 | 175 |
| NCT03530397Neoplasms · United States, Australia, France and more | 1 | Active, not recruiting | Jul 14, 2025 | 400 |
How it is read
Names in the registry
- “Volrustomig”, 14 entries
- “MEDI5752”, 4 entries
- “AZD9592 + Volrustomig”, 2 entries
- “volrustomig”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Uterine Cervical Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 3 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Renal Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.